TXA (TRANEXAMIC ACID)
Commonly Found In
Overview
TRANEXAMIC ACID is a cosmetic ingredient primarily used for SKIN BRIGHTENING and treating hyperpigmentation. It is a synthetic lysine derivative that inhibits melanin synthesis by disrupting keratinocyte-melanocyte interactions.
Also known as: TXA, trans-AMCHA, trans-4-Aminomethylcyclohexane-1-carboxylic Acid, Transamin (brand)
Key Benefits
Studies suggest that tranexamic acid may help reduce hyperpigmentation by inhibiting plasminogen activator in keratinocytes, which in turn reduces prostaglandin-mediated stimulation of melanocytes and may decrease melanin synthesis. Clinical evidence indicates topical application at 2β5% may produce measurable improvements in melasma and post-inflammatory hyperpigmentation over 8β12 weeks.
Supporting Research
- β’ Tse & Hui (2013) β pilot study of 3% topical TXA for melasma showing significant improvement (J Clin Aesthet Dermatol)
- β’ Ebrahimi & Naeini (2014) β 3% TXA vs hydroquinone 3% for melasma; comparable efficacy, better tolerability (J Res Med Sci)
- β’ Kanechorn Na Ayuthaya et al. (2012) β intradermal TXA reduces melanin index in melasma (J Cosmet Laser Ther)
Skin Compatibility Ratings
Comedogenic Rating
No comedogenic potential documented at cosmetic concentrations
Source: Cosmetic dermatology literature; no comedogenicity reports
Irritancy Rating
Considered one of the better-tolerated brightening actives; no significant irritancy reported in clinical studies at 2β5%
Source: Clinical trial safety data; Japan quasi-drug approval dossier
Typical Use Concentration
Range
2β5%
Optimal
2β3%
Japan quasi-drug approval for whitening specifies 2% concentration. EU allows use in cosmetics without a specific concentration cap, though formulations should follow SCCS guidance on safety substantiation.
Works Well With / Avoid
Works Well With
Use With Caution
Water-soluble and stable in mid-range pH (5β7). Works well in multi-active brightening formulations. Compatible with most cosmetic actives. No photosensitizing effect, making it suitable for daytime use.
Commonly Found In
Global Regulation Summary
Overview of current status across major international markets.
Detailed Regional Status
| Region | Status | Max Conc. | Conditions | Source |
|---|---|---|---|---|
| πͺπΊ EU | Unknown | - | - | Official β |
| πΊπΈ USA | Unknown | - | - | Official β |
| π―π΅ Japan | Unknown | - | - | Official β |
| π°π· Korea | Unknown | - | - | Official β |
| π¬π§ UK | Unknown | - | - | Official β |
π Why Regulations Differ
Tranexamic acid has a unique regulatory profile: approved as an oral/IV pharmaceutical for bleeding disorders globally and as a topical quasi-drug whitening active in Japan. EU permits it in cosmetics without a specific cap; the US allows cosmetic use. The pharmaceutical history provides a rich safety data background that supports cosmetic acceptance across markets.
Regulation Analysis
Category Comparison
97% of SKIN CONDITIONING ingredients (378 of 389) are banned in the EU, but this one is approved.
πΏ Natural Sources
Tranexamic acid is entirely synthetic and does not occur naturally. It is a synthetic derivative of the amino acid lysine, chemically modified for pharmaceutical and cosmetic applications.
π How It's Made
First synthesized in 1962 by Japanese researchers Shosuke and Utako Okamoto. Developed from studies on 1-(aminomethyl)-cyclohexane-4-carboxylic acid (AMCHA), found to be 27 times more powerful than previous compounds. Published in Keio Journal of Medicine in 1962. Modern synthesis produces pharmaceutical-grade material for both topical and systemic use.
π Uses in Cosmetics
Used at 2-5% for treating melasma and hyperpigmentation. Inhibits UV-induced melanin synthesis by blocking plasminogen-to-plasmin conversion in keratinocytes, reducing inflammatory mediators (arachidonic acid, prostaglandins). 3-5% concentrations for severe pigmentation. Water-soluble, stable in mid-range pH. Found in serums, creams, ampoules, often combined with niacinamide or kojic acid.
π¬ Other Applications
FDA-approved for heavy menstrual bleeding and hemophilia-related bleeding prevention. Used in surgery to reduce intraoperative blood loss (cesarean, cardiac, orthopedic). Trauma treatment (CRASH-2 trial). Postpartum hemorrhage (WOMAN trial). Dental procedures for anticoagulated patients. WHO List of Essential Medicines. May be administered orally, topically, or intravenously.
π‘ Fun Facts
- β’ Discovered in 1962 by Dr. Utako Okamoto while searching for a drug to treat post-partum hemorrhage - she found it 27 times more powerful than previous compounds
- β’ Serendipitously discovered for melasma treatment in 1979 when a patient being treated for another condition experienced unexpected skin brightening
- β’ 3% topical TXA shows efficacy comparable to hydroquinone plus dexamethasone for melasma, but with superior safety profile
Related Skin Concerns
Data Sources
- β’ Japan MHLW quasi-drug whitening active list
- β’ Ebrahimi & Naeini, J Res Med Sci 2014;19(8):753-757
- β’ Tse & Hui, J Clin Aesthet Dermatol 2013;6(7):12-17
- β’ EU CosIng database
- β’ CIR Expert Panel data
Last data verification: 2026-04-12
Related Ingredients
Ξ±-Arbutin
ALPHA-ARBUTIN
Beta-Arbutin
ARBUTIN
5-Hydroxy-2-hydroxymethyl-4-pyrone
KOJIC ACID
ALLANTOIN PABA
5-Ureidohydantoin
ALLANTOIN
AMMI MAJUS EXTRACT
Learn More
Frequently Asked Questions
What is TRANEXAMIC ACID used for in cosmetics?
TRANEXAMIC ACID is primarily used for skin conditioning in cosmetic products. It also serves as skin brightening, anti-inflammatory. The ingredient is commonly found in moisturizers, lotions, and creams.
Which countries regulate TRANEXAMIC ACID?
TRANEXAMIC ACID is approved for cosmetic use in all major markets: , with no significant restrictions.
Where can I find official regulation information about TRANEXAMIC ACID?
Official information about TRANEXAMIC ACID regulations can be found on government websites: EU CosIng database, US FDA Cosmetics page, Japan MHLW cosmetics standards, UK Government cosmetics guidance, and Korea MFDS. Always verify regulatory status with these official sources before making formulation decisions.
Disclaimer
The information on this website is for educational and informational purposes only and is not intended as medical advice. While we strive for accuracy based on official government databases, cosmetic regulations change frequently. Always consult with a qualified professional or refer to the latest official regulatory documents for compliance. We are not responsible for any actions taken based on the information provided here.